van Dam, J. L.
Verkolf, E. M. M.
Dekker, E. N.
Bonsing, B. A.
Bratlie, S. O.
Brosens, L. A. A.
Busch, O. R.
van Driel, L. M. J. W.
van Eijck, C. H. J.
Feshtali, S.
Ghorbani, P.
de Groot, D. J. A.
de Groot, J. W. B.
Haberkorn, B. C. M.
de Hingh, I. H.
van der Holt, B.
Karsten, T. M.
van der Kolk, M. B.
Labori, K. J.
Liem, M. S. L.
Loosveld, O. J. L.
Molenaar, I. Q.
Polée, M. B.
van Santvoort, H. C.
de Vos – Geelen, J.
Wumkes, M. L.
van Tienhoven, G.
Homs, M. Y. V.
Besselink, M. G.
Wilmink, J. W.
Groot Koerkamp, B.
,
Article History
Received: 12 January 2023
Accepted: 30 June 2023
First Online: 7 August 2023
Declarations
:
: The study protocol was approved by the Medical Ethics Committee of Erasmus MC University Medical Center (MEC 2021–0002) and registered with the European drug regulatory affairs Clinical Trials database (EudraCT 2020‐005141‐16). The trial is conducted according to the principles of the Declaration of Helsinki and in accordance with the Medical Research Involving Human Subjects act.The treating physician will inform eligible patients about the study and will explain the aims, methods, anticipated benefits, and potential hazards. Written informed consent will be obtained before enrollment in the trial and before any study related procedures take place.
: Not applicable.
: The authors declare no competing interests.